Product Information
CHLORDIAZEPOXIDE-CLIDINIUM CAP is a generic product labeled by Chartwell RX LLC, priced at $0.2561 per EA under NDC 62135069612. Its NADAC has been published 208 times since Oct 12, 2022.
FDA first approved this application on Oct 20, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5; 2.5 mg/1; mg/1
Manufacturer
Chartwell RX LLCNDC
62135069612
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA213530FDA Approved
10/20/2020
TE Code
AB
On Market Since
10/20/2020
Pharmacological Classes
Price Statistics
The NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has been published 208 times since Oct 12, 2022, and over the history we have for it it has declined 23.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2561 per EA |
|---|---|
| All-time high | $0.5272 (Oct 16, 2024) |
| All-time low | $0.2088 (Apr 19, 2023) |
| 52-week high | $0.3051 |
| 52-week low | $0.2405 |
| Median price | $0.3044 |
| Average price | $0.3257 |
| Largest weekly change | +88.8% (May 17, 2023) |
| Weeks tracked | 208 |
| Tracking since | Oct 12, 2022 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Chlordiazepoxide Hydrochloride and Clidinium Bromide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anticholinergic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CHLORDIAZEPOXIDE-CLIDINIUM CAP?
The current National Average Drug Acquisition Cost (NADAC) for CHLORDIAZEPOXIDE-CLIDINIUM CAP, manufactured by Chartwell RX LLC, is $0.2561 per EA (NDC 62135069612), effective Sep 30, 2026.
How has the price of CHLORDIAZEPOXIDE-CLIDINIUM CAP changed over time?
Over the history we have for it, the NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has declined 23.3%. It has been tracked across 208 weekly CMS publications since Oct 12, 2022.
What are the highest and lowest recorded NADAC prices for CHLORDIAZEPOXIDE-CLIDINIUM CAP?
Since Oct 12, 2022, the NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has ranged from a low of $0.2088 (Apr 19, 2023) to a high of $0.5272 (Oct 16, 2024), with a median of $0.3044 per EA.
Are there cheaper alternatives to CHLORDIAZEPOXIDE-CLIDINIUM CAP?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CHLORDIAZEPOXIDE-CLIDINIUM CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures CHLORDIAZEPOXIDE-CLIDINIUM CAP?
CHLORDIAZEPOXIDE-CLIDINIUM CAP (NDC 62135069612) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.